Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial

Tools
- Tools
+ Tools

Corrie, Pippa G., Marshall, A. (Andrea)‏, Nathan, P D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J. et al.
(2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852. doi:10.1093/annonc/mdy229

[img]
Preview
PDF
WRAP-Adjuvant-bevacizumab-melanoma-high-risk-Marshall-2018.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (366Kb) | Preview
Official URL: https://doi.org/10.1093/annonc/mdy229

Request Changes to record.

Abstract

Background

Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.

Patients and methods

Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers.

Results

Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21).

Conclusions

Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine > Warwick Medical School
SWORD Depositor: Library Publications Router
Library of Congress Subject Headings (LCSH): Bevacizumab, Melanoma, Cancer -- Patients -- Treatment
Journal or Publication Title: Annals of Oncology
Publisher: Oxford University Press
ISSN: 0923-7534
Official Date: 1 August 2018
Dates:
DateEvent
1 August 2018Published
13 July 2018Available
22 June 2018Accepted
Volume: 29
Number: 8
Page Range: pp. 1843-1852
DOI: 10.1093/annonc/mdy229
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
C7535/A6408 Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C2195/A8466 Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
UNSPECIFIEDRochehttp://dx.doi.org/10.13039/100004337
UNSPECIFIEDCambridge University Hospitalshttp://dx.doi.org/10.13039/501100002926

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us